Structural Elucidation and Antidiabetic Activity of Polysaccharides From the Parasitic Plant Orobanche Cumana

Why It Matters

Transforming a major agricultural pest into a bioactive polysaccharide offers a sustainable new avenue for diabetes therapeutics, addressing safety concerns of current drugs and adding value to crop waste.

Key Takeaways

• OCP‑3 is a rhamnogalacturonan‑I polysaccharide with 66 kDa MW
• OCP‑3 inhibited α‑amylase (IC₅₀ = 98.5 µg mL⁻¹) and α‑glucosidase (IC₅₀ = 56.1 µg mL⁻¹)
• In diabetic mice, OCP‑3 lowered fasting glucose from 31.3 to 17.2 mM
• OCP‑3 restored serum insulin to 10.34 µU mL⁻¹, matching metformin levels
• No hematological or hepatic toxicity observed after 28‑day OCP‑3 treatment

Pulse Analysis

Diabetes remains a global health crisis, driving demand for therapies that combine efficacy with safety. Plant‑derived polysaccharides have emerged as multi‑target agents capable of modulating glucose metabolism, oxidative stress, and inflammation. While many edible plants have been explored, the parasitic weed Orobanche cumana—traditionally a costly pest for sunflower growers—has been largely overlooked despite its historic use in Uyghur medicine for blood‑sugar regulation. Leveraging modern extraction techniques, scientists have turned this liability into a resource, extracting three distinct polysaccharide fractions and pinpointing the alkaline‑soluble OCP‑3 as the most bioactive.

OCP‑3’s structural profile—a rhamnogalacturonan‑I backbone enriched with rhamnose and galacturonic acid—confers a low molecular weight and abundant functional groups that enhance solubility and interaction with biological targets. In vitro assays revealed potent free‑radical scavenging and enzyme inhibition, rivaling the pharmaceutical benchmark acarbose. When administered to streptozotocin‑induced diabetic mice, OCP‑3 not only halved fasting glucose levels but also normalized insulin secretion and improved oral glucose tolerance, mirroring metformin’s performance. Histological examinations confirmed preservation of pancreatic islets and reduced hepatic lipid accumulation, underscoring a comprehensive organ‑protective effect.

The implications extend beyond therapeutic promise. By valorizing Orobanche cumana, growers can offset crop losses through a high‑value nutraceutical derived from the same biomass, aligning agricultural sustainability with pharmaceutical innovation. Future work should explore human pharmacokinetics, scale‑up purification, and regulatory pathways, positioning OCP‑3 as a candidate for functional foods or adjunct diabetes treatments. This convergence of waste reduction and health benefit exemplifies the emerging circular economy in biotech.